Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.

Choon Kee Lee, MD, Jeff Kaiser, Pharm., D., Han Myint, FRCP, FRCPath, Mary Berg, MD, J. Fred Kolhouse, MD, William Robinson, MD

Blood (2009) 114 (22): 3404.

https://doi.org/10.1182/blood.V114.22.3404.3404

Published: 2009

Journal Articles

Presence of Dysregulated Immune Recovery (IMD) Following Autotransplant May Change the Type of Predominant Serum Light Chain and Elevate the Level in Patients with Multiple Myeloma (MM).

Choon Kee Lee, MD, Mary Berg, MD, John Ryder, Han Myint, FRCP, FRCPath, J. Fred Kolhouse, MD, William Robinson, MD

Blood (2009) 114 (22): 4870.

https://doi.org/10.1182/blood.V114.22.4870.4870

Published: 2009

Journal Articles

Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM).

Choon Kee Lee, MD, Qi Wei, Director, Laboratory, Develpment, Molecular, Diagnostics, Mark Lovell, Associate, Professor, Karen Swisshelm, Co-Director, John Ryder, Han Myint, FRCP, FRCPath, J. Fred Kolhouse, MD, William Robinson, MD

Blood (2009) 114 (22): 1807.

https://doi.org/10.1182/blood.V114.22.1807.1807

Published: 2009

Journal Articles

Alkylator-Induced DNA Damage Response in Multiple Myeloma (MM) Cells Is Amplified by Histone Deacetylase (HDAC) Inhibition, Resulting in Significant Synergism in Cell Death

Choon Kee Lee, MD, Shuiliang Wang, M.D., Xiaoping Huang, M.D., John Ryder, M.D., Peter Ordentlich, PhD, Bolin Liu, M.D.

Blood (2008) 112 (11): 5157.

https://doi.org/10.1182/blood.V112.11.5157.5157

Published: 2008

Journal Articles

Role of MicroRNAs in Resistance to Dexamethasone in Multiple Myeloma Cell Lines

Qaiser Bashir, MD, Lynne Bemis, Ph.D, William Robinson, MD, Bolin Liu, Ph.D, Shuiliang Wang, Carol Amato, Elizabeth Riley, MD, Choon Kee Lee, MD

Blood (2008) 112 (11): 3680.

https://doi.org/10.1182/blood.V112.11.3680.3680

Published: 2008

Journal Articles

Intensive Induction Therapy with Melphalan 50 mg/m 2 (MEL50) for Patients with AL Amyloidosis.

Choon Kee Lee, MD, Han Myint, MD, Peterson J. Glen, ACNP, Kolhouse J. Fred, MD, Hannis W. Thompson, MD

Blood (2007) 110 (11): 5122.

https://doi.org/10.1182/blood.V110.11.5122.5122

Published: 2007

Journal Articles

2-Chlorodeoxyadenosine (2-CDA) and Dexamethasone Induce Apoptosis in Multiple Myeloma (MM) Via Different Mechanisms.

Bolin Liu, MD, MS, Zeying Fang, MD, Jian Ma, MS, Thomas E. Dillon, MS, Tim E. Byers, MD, MPH, Ann D. Thor, MD, Choon Kee Lee, MD

Blood (2007) 110 (11): 4792.

https://doi.org/10.1182/blood.V110.11.4792.4792

Published: 2007

Journal Articles

Treatment of Extranodal Marginal Zone Lymphoma and Primary Cutaneous B Cell Lymphoma with Rituximab: A Single Institution Experience.

Robert Chen, MD, Glen Peterson, NP, Diana Vucurevich, NP, Choon-kee Lee, MD, William Robinson, MD, Han Myint, MD, FRCP

Blood (2007) 110 (11): 4502.

https://doi.org/10.1182/blood.V110.11.4502.4502

Published: 2007

Journal Articles

B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.

Peter Kabos, MD, Qaiser Bashir, MD, Robert Chen, MD, JoAnn Lindenfeld, MD, Han Myint, MD, Choon Kee Lee, MD

Blood (2007) 110 (11): 4773.

https://doi.org/10.1182/blood.V110.11.4773.4773

Published: 2007

Journal Articles

The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.

Maurizio Zangari, MD, Kevin B. Najarian, MS, Dixie L. Esseltine, MD, Choon-Kee Lee, MD, Bart Barlogie, MD, PhD, Francesca Elice, MD, Michael J. Burns, BS, BA, Shmuel Yaccoby, PhD, Paul Richardson, MD, Pieter Sonneveld, MD

Blood (2005) 106 (11): 510.

https://doi.org/10.1182/blood.V106.11.510.510

Published: 2005

Journal Articles

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Athanasios Fassas, MD, Erik Rasmussen, Raymond Thertulien, MD, PhD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 1480.

https://doi.org/10.1182/blood.V104.11.1480.1480

Published: 2004

Journal Articles

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Athanasios Fassas, MD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Julian Terry, Maurizio Zangari, MD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 932.

https://doi.org/10.1182/blood.V104.11.932.932

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Blood (2004) 104 (11): 784.

https://doi.org/10.1182/blood.V104.11.784.784

Published: 2004

Journal Articles

Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Choon-Kee Lee, MD, Bart Barlogie, MD, PhD, Kevin Najarian, Seung-Hee Kang, MD, Shmuel Yaccoby, PhD, Dixie Esseltine, MD, FRCPC, Julie M. Stover, BA, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4910.

https://doi.org/10.1182/blood.V104.11.4910.4910

Published: 2004

Journal Articles

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Choon-Kee Lee, MD, Annick E. Tricot, Athanasios Fassas, MD, Elias Anaissie, MD, Klaus Hollmig, MD, Raymond Thertulien, MD, Giampaolo Talamo, MD, Frits van Rhee, MD, PhD, Julie M. Stover, BA, Louis Fink, MD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4914.

https://doi.org/10.1182/blood.V104.11.4914.4914

Published: 2004

Journal Articles

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampaolo Talamo, MD, Athanasios Fassas, MD, Choon-Kee Lee, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2399.

https://doi.org/10.1182/blood.V104.11.2399.2399

Published: 2004

Journal Articles

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

John Shaughnessy, PhD, Frank Zhan, PhD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, MD, Maurizio Zangari, MD, Choon-Kee Lee, MD, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 4935.

https://doi.org/10.1182/blood.V104.11.4935.4935

Published: 2004

Journal Articles

Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years.

Choon Kee Lee, MD, Bart Barlogie, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, PhD, Maurizio Zangari, MD, Erik Rasmussen, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 540.

https://doi.org/10.1182/blood.V104.11.540.540

Published: 2004

NARROW

An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.

Presence of Dysregulated Immune Recovery (IMD) Following Autotransplant May Change the Type of Predominant Serum Light Chain and Elevate the Level in Patients with Multiple Myeloma (MM).

Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM).

Alkylator-Induced DNA Damage Response in Multiple Myeloma (MM) Cells Is Amplified by Histone Deacetylase (HDAC) Inhibition, Resulting in Significant Synergism in Cell Death

Role of MicroRNAs in Resistance to Dexamethasone in Multiple Myeloma Cell Lines

Intensive Induction Therapy with Melphalan 50 mg/m 2 (MEL50) for Patients with AL Amyloidosis.

2-Chlorodeoxyadenosine (2-CDA) and Dexamethasone Induce Apoptosis in Multiple Myeloma (MM) Via Different Mechanisms.

Treatment of Extranodal Marginal Zone Lymphoma and Primary Cutaneous B Cell Lymphoma with Rituximab: A Single Institution Experience.

B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.

The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only